SECENDS - BSX

2025

Q4 4 filings

Nov

2026 Compensation Plans Approved

Annual bonus plan with 0-225% payout range, performance shares tied to TSR and organic sales growth

8-K

Nov

Q3 2025 Results

Financial data not clearly visible in provided XBRL format

10-Q

Oct

Director John E. Sununu Not Standing for Re-election

John E. Sununu departing 2026 Annual Meeting after 17 years

8-K

Oct

Q3 Earnings

Q3 2025 financial results for quarter ended Sept 30, 2025

8-K

Q3 3 filings

Sep

EVP Peripheral Interventions Retired

Jeffrey B. Mirviss retiring Dec 1, 2025, $705K base salary

8-K

Aug

Q2 2025 Results

Revenue and EPS data not clearly extractable from XBRL format provided

10-Q

Jul

Q2 Earnings

Q2 2025 financial results announced

8-K

Q2 5 filings

May

Discontinued ACURATE Valve Systems

Worldwide discontinuation of ACURATE neo2 and Prime Aortic Valve Systems

8-K

May

2025 Annual Shareholder Meeting Results

All 10 directors elected, say-on-pay approved, simple majority vote proposal passed

8-K

May

Q1 2025 Results

Unable to extract revenue and EPS - filing contains only XBRL metadata without actual financial values

10-Q

Apr

CFO Transition

Daniel Brennan retiring as CFO, Jonathan Monson promoted effective June 30

8-K

Apr

Q1 2025 Earnings

Q1 2025 financial results announced

8-K

Q1 6 filings

Mar

2025 Proxy Statement

CEO comp: Not disclosed, Say-on-pay: Advisory vote scheduled

DEF 14A

Feb

Euro Debt Offering

€1.5B notes issued (€850M 2031 at 3.0%, €650M 2034 at 3.25%)

8-K

Feb

FY2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL data

📌 Multiple strategic acquisitions completed including Silk Road Medical (Sep 2024), Axonics (Nov 2024), and Intera Oncology (Nov 2024)

10-K

Feb

Director Not Standing for Re-election

Charles J. Dockendorff stepping down after 10 years

8-K

Feb

Q4 2024 Earnings

Q4 and full year 2024 financial results announced

8-K

Jan

LOTUS Edge Valve Settlement

Court preliminary approval Jan 8, final hearing Mar 25

8-K

2024

Q4 5 filings

Nov

2025 Compensation Plans Approved

Annual bonus plan with 0-225% payout range, performance shares with 0-200% range

8-K

Nov

Acquired Axonics Inc

$3.7B equity value, $71/share cash

8-K

Nov

Resumed AVANT GUARD Clinical Trial

Trial studying drug-naïve patients with persistent atrial fibrillation resumed after data monitoring committee assessment

8-K

Nov

Q3 2024 Results

Financial figures not extractable from XBRL metadata provided

10-Q

Oct

Q3 Earnings

Q3 2024 financial results for quarter ended Sept 30

8-K

Q3 3 filings

Aug

Q2 2024 Results

Unable to extract revenue and EPS figures from provided XBRL taxonomy data

10-Q

Jul

New Director Appointed

David C. Habiger appointed to Board, ~$256K prorated compensation

8-K

Jul

Q2 2024 Earnings

Q2 2024 financial results announced

8-K

Q2 4 filings

May

New Director Appointed & Credit Line Extended

Dr. Cheryl Pegus joins board, $2.75B credit facility extended to 2029

8-K

May

Annual Shareholder Meeting

9 directors elected, bylaws amended for proxy rules

8-K

May

Q1 2024 Results

Unable to extract revenue and EPS figures from provided XBRL data

10-Q

Apr

Q1 Earnings

Q1 2024 financial results for quarter ended March 31, 2024

8-K